Guest View
User: Pass: | become a member


BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Courtesy of Benzinga.

NuPathe Inc. (NASDAQ: PATH), today announced that it has granted time-based stock options to Armando Anido, the Company’s newly appointed chief executive officer, pursuant to the NASDAQ inducement grant exception. The inducement grants were approved by the Company’s board of directors and are being made as an inducement material to Mr. Anido’s acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). NuPathe previously announced that Mr. Anido was appointed chief executive officer and a member of the Company’s board of directors effective July 25, 2012.


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!




You must be logged in to make a comment.
You can sign up for a membership or get a free SWW trial or log in.

Dashboard

 Sector Performances (Today)

 Thermal Imaging